oxybutynin has been researched along with Urge Incontinence in 30 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated whether combination therapy with transcutaneous electrical nerve stimulation and oxybutynin results in a superior treatment response compared to either therapy alone in children with urge incontinence." | 9.24 | Transcutaneous Electrical Nerve Stimulation Combined with Oxybutynin is Superior to Monotherapy in Children with Urge Incontinence: A Randomized, Placebo Controlled Study. ( Borch, L; Hagstroem, S; Kamperis, K; Rittig, S; Siggaard, CV, 2017) |
| "In this randomized, double-blind, active-controlled, parallel-group, multicenter, Phase IIIb trial conducted in Germany, male and female outpatients aged >or=18 years with documented urinary frequency (>or=8 micturitions/24 hours) plus urge incontinence (>or=5 episodes/week) were randomized to receive oral treatment with trospium chloride 15 mg TID or oxybutynin hydrochloride 2." | 9.14 | Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. ( Bödeker, RH; Madersbacher, H; Palmtag, H; Stöhrer, M; Zellner, M, 2009) |
| " In this post hoc analysis we evaluated the efficacy and tolerability of trospium chloride treatment for urinary urge incontinence (UUI) with focus on flexible dosing." | 9.14 | Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. ( Bödeker, RH; Madersbacher, H; Neumeister, C; Zellner, M, 2010) |
| "To compare, in a retrospective observational cohort study, the efficacy, tolerability and safety of propiverine and oxybutynin in children with urge incontinence (UI) due to overactive bladder." | 7.76 | Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study. ( Alloussi, S; Bock, P; Braun, R; Gerhardt, U; Heinrich, M; Hellmis, E; Horn, W; Madersbacher, H; Marschall-Kehrel, D; Mürtz, G; Niklas, K; Raabe, M; Rössler, T; Schultz-Lampel, D; Seibt, B; Siemer, S; Strugala, G; Walter, H; Wiedeking, B, 2010) |
| "We evaluated whether combination therapy with transcutaneous electrical nerve stimulation and oxybutynin results in a superior treatment response compared to either therapy alone in children with urge incontinence." | 5.24 | Transcutaneous Electrical Nerve Stimulation Combined with Oxybutynin is Superior to Monotherapy in Children with Urge Incontinence: A Randomized, Placebo Controlled Study. ( Borch, L; Hagstroem, S; Kamperis, K; Rittig, S; Siggaard, CV, 2017) |
| "Seventy girls and 27 boys with clinically diagnosed OAB and urge incontinence were randomly allocated to placebo, oxybutynin, or bladder training (branch I), and 89 girls and 16 boys with clinically diagnosed DV to either cognitive treatment or pelvic floor training (branch II)." | 5.19 | Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence. ( Bachmann, H; Bael, A; de Jong, TP; Hirche, H; Hjälmås, K; Hoebeke, P; Jodal, U; John, U; Lax, H; Misselwitz, J; Nijman, RJ; Tamminen-Möbius, T; van Gool, JD; Walle, JV; Winkler-Seinstra, P, 2014) |
| "In this randomized, double-blind, active-controlled, parallel-group, multicenter, Phase IIIb trial conducted in Germany, male and female outpatients aged >or=18 years with documented urinary frequency (>or=8 micturitions/24 hours) plus urge incontinence (>or=5 episodes/week) were randomized to receive oral treatment with trospium chloride 15 mg TID or oxybutynin hydrochloride 2." | 5.14 | Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. ( Bödeker, RH; Madersbacher, H; Palmtag, H; Stöhrer, M; Zellner, M, 2009) |
| " In this post hoc analysis we evaluated the efficacy and tolerability of trospium chloride treatment for urinary urge incontinence (UUI) with focus on flexible dosing." | 5.14 | Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. ( Bödeker, RH; Madersbacher, H; Neumeister, C; Zellner, M, 2010) |
| " This study evaluates the effects of long-acting oxybutynin and tolterodine on short-term memory and attention in children with urgency and urge incontinence." | 5.13 | The effects of anticholinergic drugs on attention span and short-term memory skills in children. ( Giramonti, KM; Halpern, LF; Kogan, BA, 2008) |
| "Short-term treatment using oral extended-release oxybutynin 5 mg once daily was safe and well tolerated, with no delirium, in older female nursing home participants with mild to severe dementia." | 5.13 | Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. ( Davey, C; Lackner, TE; McCarthy, TC; Monigold, M; Wyman, JF, 2008) |
| "To compare, in a retrospective observational cohort study, the efficacy, tolerability and safety of propiverine and oxybutynin in children with urge incontinence (UI) due to overactive bladder." | 3.76 | Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study. ( Alloussi, S; Bock, P; Braun, R; Gerhardt, U; Heinrich, M; Hellmis, E; Horn, W; Madersbacher, H; Marschall-Kehrel, D; Mürtz, G; Niklas, K; Raabe, M; Rössler, T; Schultz-Lampel, D; Seibt, B; Siemer, S; Strugala, G; Walter, H; Wiedeking, B, 2010) |
| "Fifty women aged 65 and older with urge incontinence and cognitive impairment." | 2.76 | Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. ( Davey, C; Lackner, TE; McCarthy, TC; Monigold, M; Wyman, JF, 2011) |
| "To evaluate the efficacy and tolerability of extended-release oxybutynin in combination with the alpha1-blocker tamsulosin in reducing lower urinary tract symptoms in men." | 2.73 | Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. ( Aquilina, JW; Armstrong, RB; Chen, A; MacDiarmid, SA; Nitti, VW; Orman, C; Peters, KM, 2008) |
| "Complete freedom from urge incontinence was reported by significantly more patients taking oxybutynin than tolterodine at last observation (23." | 2.72 | Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. ( Anderson, RU; Barada, JH; Goldberg, RP; Kell, S; MacDiarmid, S; Serels, S, 2006) |
| "Daytime wetting is a common problem with various causes that can usually be identified through a careful history, thorough physical examination, and urinalysis." | 2.43 | An approach to daytime wetting in children. ( Leung, AK; Robson, WL, 2006) |
| "Oxybutynin was not associated with a short-term increased risk of hospital visit for falls, fractures or delirium compared to tolterodine." | 1.37 | Risk of serious falls associated with oxybutynin and tolterodine: a population based study. ( Gomes, T; Ho, JM; Juurlink, DN; Mamdani, MM; Schneeweiss, S, 2011) |
| "Repeated discrete outcome variables such as count measurements often arise in pharmacodynamic experiments." | 1.36 | Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements. ( Aarons, L; Ogungbenro, K, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (40.00) | 29.6817 |
| 2010's | 17 (56.67) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Komesu, YM | 1 |
| Schrader, RM | 1 |
| Rogers, RG | 1 |
| Sapien, RE | 1 |
| Mayer, AR | 1 |
| Ketai, LH | 1 |
| Borch, L | 1 |
| Hagstroem, S | 1 |
| Kamperis, K | 1 |
| Siggaard, CV | 1 |
| Rittig, S | 1 |
| Barroso, U | 1 |
| van Gool, JD | 2 |
| de Jong, TP | 2 |
| Winkler-Seinstra, P | 1 |
| Tamminen-Möbius, T | 1 |
| Lax, H | 2 |
| Hirche, H | 2 |
| Nijman, RJ | 2 |
| Hjälmås, K | 1 |
| Jodal, U | 1 |
| Bachmann, H | 1 |
| Hoebeke, P | 2 |
| Walle, JV | 1 |
| Misselwitz, J | 1 |
| John, U | 1 |
| Bael, A | 2 |
| Kosilov, KV | 1 |
| Loparev, SA | 1 |
| Krasnykh, MA | 1 |
| Kosilova, LV | 1 |
| Lauti, M | 1 |
| Herbison, P | 1 |
| Hay-Smith, J | 1 |
| Ellis, G | 1 |
| Wilson, D | 1 |
| Sixt, R | 1 |
| Verhulst, J | 1 |
| MacDiarmid, SA | 1 |
| Peters, KM | 1 |
| Chen, A | 1 |
| Armstrong, RB | 1 |
| Orman, C | 1 |
| Aquilina, JW | 1 |
| Nitti, VW | 1 |
| Wang, AC | 1 |
| Chen, MC | 1 |
| Kuo, WY | 1 |
| Lin, YH | 1 |
| Wang, YC | 1 |
| Lo, TS | 1 |
| Alloussi, S | 2 |
| Mürtz, G | 1 |
| Braun, R | 1 |
| Gerhardt, U | 1 |
| Heinrich, M | 1 |
| Hellmis, E | 1 |
| Horn, W | 1 |
| Marschall-Kehrel, D | 1 |
| Niklas, K | 1 |
| Raabe, M | 1 |
| Rössler, T | 1 |
| Seibt, B | 1 |
| Siemer, S | 1 |
| Schultz-Lampel, D | 1 |
| Walter, H | 1 |
| Wiedeking, B | 1 |
| Bock, P | 1 |
| Strugala, G | 1 |
| Madersbacher, H | 3 |
| Zellner, M | 2 |
| Palmtag, H | 1 |
| Stöhrer, M | 1 |
| Bödeker, RH | 2 |
| Cartwright, R | 2 |
| Srikrishna, S | 2 |
| Cardozo, L | 2 |
| Robinson, D | 2 |
| Burgio, KL | 1 |
| Goode, PS | 1 |
| Richter, HE | 1 |
| Markland, AD | 1 |
| Johnson, TM | 1 |
| Redden, DT | 1 |
| Ogungbenro, K | 1 |
| Aarons, L | 1 |
| Neumeister, C | 1 |
| Keller, DL | 1 |
| Lackner, TE | 2 |
| Wyman, JF | 2 |
| McCarthy, TC | 2 |
| Monigold, M | 2 |
| Davey, C | 2 |
| Gomes, T | 2 |
| Juurlink, DN | 2 |
| Mamdani, MM | 2 |
| Ho, JM | 1 |
| Schneeweiss, S | 1 |
| Nilsson, FO | 1 |
| Linnér, L | 1 |
| Samuelsson, E | 1 |
| Milsom, I | 1 |
| Dede, H | 1 |
| Dolen, İ | 1 |
| Dede, FS | 1 |
| Sivaslioglu, AA | 1 |
| Anderson, RU | 1 |
| MacDiarmid, S | 1 |
| Kell, S | 1 |
| Barada, JH | 1 |
| Serels, S | 1 |
| Goldberg, RP | 1 |
| Kafri, R | 2 |
| Langer, R | 1 |
| Dvir, Z | 1 |
| Katz-Leurer, M | 2 |
| Robson, WL | 1 |
| Leung, AK | 1 |
| Shames, J | 1 |
| Raz, M | 1 |
| Giramonti, KM | 1 |
| Kogan, BA | 1 |
| Halpern, LF | 1 |
| Duh, D | 1 |
| Vandevijver, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Protocol for Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence An RCT: Hypnotherapy Or Pharmacotherapy[NCT01829425] | 165 participants (Actual) | Interventional | 2013-04-22 | Completed | |||
| The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.[NCT02973659] | 61 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| Enhancing Conservative Treatment for Urge Incontinence[NCT00223821] | 166 participants (Actual) | Interventional | 2003-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overactive Bladder questionnaire Short Form Quality of Life. Higher scores are better (better quality of life) and lower scores are worse (poorer quality of life). sub-scale score range 0-100. (NCT01829425)
Timeframe: 6 months
| Intervention | sub-scale scores (Least Squares Mean) |
|---|---|
| Hypnotherapy | 75.85 |
| Anticholinergic Medications | 80.19 |
Overactive Bladder questionnaire-Short Form Quality of Life. Higher scores are better (better quality of life) and lower scores are worse (poorer quality of life). sub-score range 0-100. (NCT01829425)
Timeframe: 2 months
| Intervention | sub-scale scores (Least Squares Mean) |
|---|---|
| Hypnotherapy | 73.96 |
| Anticholinergic Medications | 74.86 |
Overactive Bladder questionnaire-Short Form Quality of Life. Higher scores are better (higher quality of life) and lower scores are worse (poorer quality of life). score range 0-100. (NCT01829425)
Timeframe: 12 months
| Intervention | sub-scale scores (Least Squares Mean) |
|---|---|
| Hypnotherapy | 75.71 |
| Anticholinergic Medications | 81.57 |
Overactive Bladder Questionnaire Short Form symptom bother Scale. Sub-Scale range 0-100. Higher numbers are worse (more bother) and lower numbers are better (less bother) (NCT01829425)
Timeframe: 2 months
| Intervention | scores on a sub-scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | 38.17 |
| Anticholinergic Medications | 35.33 |
Overactive Bladder Questionnaire Short Form symptom bother. Sub-scale range 0-100. Higher numbers are worse (more bother) and lower numbers are better (less bother) (NCT01829425)
Timeframe: 12 months
| Intervention | sub-scale scores (Least Squares Mean) |
|---|---|
| Hypnotherapy | 32.27 |
| Anticholinergic Medications | 30.74 |
Overactive Bladder Questionnaire Short Form symptom bother. Sub-scale range 0-100. Higher numbers are worse (more bother) and lower numbers are better (less bother) (NCT01829425)
Timeframe: 6 months
| Intervention | sub-scale scores (Least Squares Mean) |
|---|---|
| Hypnotherapy | 34.61 |
| Anticholinergic Medications | 27.93 |
Differences comparing hypnotherapy to pharmacotherapy percent change in median UUI episodes (NCT01829425)
Timeframe: 6 months
| Intervention | percentage change in median UUI episodes (Median) |
|---|---|
| Hypnotherapy | 85.7 |
| Anticholinergic Medications | 83.3 |
Percent change in median UUI episodes from baseline to 12 months with comparison made between hypnotherapy & pharmacotherapy (NCT01829425)
Timeframe: 12 months
| Intervention | percentage change in median UUI episodes (Median) |
|---|---|
| Hypnotherapy | 85.7 |
| Anticholinergic Medications | 80.0 |
Percent change in UUI episodes from baseline to 2 months with comparison made between hypnotherapy & pharmacotherapy (NCT01829425)
Timeframe: Baseline and 2 month follow-up
| Intervention | percentage change in median UUI episodes (Median) |
|---|---|
| Hypnotherapy | 73 |
| Anticholinergic Medications | 88.6 |
number of voids on 3-day bladder diary (NCT01829425)
Timeframe: 12 months
| Intervention | counts (Mean) |
|---|---|
| Hypnotherapy | 25.74 |
| Anticholinergic Medications | 25.37 |
number of voids on 3-day bladder diary (NCT01829425)
Timeframe: 6 months
| Intervention | counts (Mean) |
|---|---|
| Hypnotherapy | 25.58 |
| Anticholinergic Medications | 24.28 |
Total Number of voids on 3-day bladder diary. (NCT01829425)
Timeframe: 2 months
| Intervention | counts (Mean) |
|---|---|
| Hypnotherapy | 26.4 |
| Anticholinergic Medications | 25.35 |
Percent change from baseline in weekly frequency of incontinent episodes at 12-months post-treatment, derived from baseline and 12-month seven-day bladder diaries (NCT00223821)
Timeframe: Baseline and 12 months post-treatment
| Intervention | percent change (Mean) |
|---|---|
| Drug Therapy Alone | -82.0 |
| Drug Therapy + Behavioral Training | -75.2 |
Percent change from baseline in weekly frequency of incontinent episodes immediately post-treatment, derived from baseline and week 8 seven-day bladder diaries. (NCT00223821)
Timeframe: Baseline and immediately post-treatment - week 8
| Intervention | percentage change (Mean) |
|---|---|
| Drug Therapy Alone | -88.5 |
| Drug Therapy + Behavioral Training | -78.3 |
1 review available for oxybutynin and Urge Incontinence
| Article | Year |
|---|---|
An approach to daytime wetting in children.
Topics: Arousal; Benzhydryl Compounds; Child; Child, Preschool; Constipation; Cresols; Diurnal Enuresis; Hum | 2006 |
20 trials available for oxybutynin and Urge Incontinence
| Article | Year |
|---|---|
Hypnotherapy or medications: a randomized noninferiority trial in urgency urinary incontinent women.
Topics: Adult; Aged; Female; Humans; Hypnosis; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Single-B | 2020 |
Transcutaneous Electrical Nerve Stimulation Combined with Oxybutynin is Superior to Monotherapy in Children with Urge Incontinence: A Randomized, Placebo Controlled Study.
Topics: Adolescent; Child; Child, Preschool; Combined Modality Therapy; Double-Blind Method; Female; Humans; | 2017 |
Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence.
Topics: Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Mandelic Acids | 2014 |
[Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].
Topics: Aged; Benzhydryl Compounds; Benzilates; Cresols; Dose-Response Relationship, Drug; Double-Blind Meth | 2014 |
Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence: a pilot randomised trial.
Topics: Biofeedback, Psychology; Cholinergic Antagonists; Female; Follow-Up Studies; Humans; Mandelic Acids; | 2008 |
The relevance of urodynamic studies for Urge syndrome and dysfunctional voiding: a multicenter controlled trial in children.
Topics: Adolescent; Age Factors; Chi-Square Distribution; Child; Electromyography; Female; Follow-Up Studies | 2008 |
Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study.
Topics: Aged; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Man | 2008 |
Urgency-free time interval as primary endpoint for evaluating the outcome of a randomized OAB treatment.
Topics: Adult; Electric Stimulation Therapy; Endpoint Determination; Female; Health Surveys; Humans; Inciden | 2009 |
Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzilates; Double-Blind Method; Female; Humans; Male; M | 2009 |
Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Epidemiologic Methods; Female; Goals; Hum | 2011 |
Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women.
Topics: Aged; Behavior Therapy; Combined Modality Therapy; Female; Humans; Mandelic Acids; Middle Aged; Musc | 2010 |
Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence.
Topics: Adolescent; Adult; Aged; Benzilates; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Midd | 2010 |
Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder.
Topics: Adult; Epidemiologic Methods; Female; Humans; Mandelic Acids; Medical Records; Muscarinic Antagonist | 2011 |
Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Cholinergic Antagonists; Cognition Disorders; Delayed-Action Preparations; | 2011 |
What is the success of drug treatment in urge urinary incontinence? What should be measured?
Topics: Adult; Benzhydryl Compounds; Benzilates; Cresols; Female; Humans; Mandelic Acids; Middle Aged; Musca | 2013 |
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Demography; Drug-Related Side Effects and Adverse Reacti | 2006 |
Rehabilitation vs drug therapy for urge urinary incontinence: short-term outcome.
Topics: Aged; Exercise Therapy; Female; Follow-Up Studies; Humans; Mandelic Acids; Middle Aged; Muscarinic A | 2007 |
Rehabilitation versus drug therapy for urge urinary incontinence: long-term outcomes.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Mandelic Acids; Middle Aged; Muscarinic Antagonists; | 2008 |
The effects of anticholinergic drugs on attention span and short-term memory skills in children.
Topics: Attention; Benzhydryl Compounds; Child; Child Behavior; Cholinergic Antagonists; Cognition; Cresols; | 2008 |
Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence.
Topics: Accidental Falls; Administration, Oral; Aged; Aged, 80 and over; Cognition; Confusion; Delayed-Actio | 2008 |
9 other studies available for oxybutynin and Urge Incontinence
| Article | Year |
|---|---|
When Should We Offer Parasacral Transcutaneous Electrical Nerve Stimulation for Pediatric Patients with Lower Urinary Tract Dysfunction?
Topics: Child; Humans; Mandelic Acids; Transcutaneous Electric Nerve Stimulation; Urinary Bladder, Overactiv | 2017 |
Topics: Child; Humans; Mandelic Acids; Transcutaneous Electric Nerve Stimulation; Urinary Incontinence; Urin | 2018 |
Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
Topics: Adolescent; Benzilates; Child; Child, Preschool; Cholinergic Antagonists; Epidemiologic Methods; Fem | 2010 |
Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements.
Topics: Algorithms; Clinical Trials as Topic; Computer Simulation; Controlled Clinical Trials as Topic; Dose | 2010 |
Idiopathic urgency urinary incontinence.
Topics: Cholinergic Antagonists; Female; Humans; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Prescr | 2010 |
Comparative adherence to oxybutynin or tolterodine among older patients.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Cohort Studies; Cresols; Databases, Factual; Drug Pre | 2012 |
Risk of serious falls associated with oxybutynin and tolterodine: a population based study.
Topics: Accidental Falls; Aged; Benzhydryl Compounds; Cresols; Emergency Service, Hospital; Hospitalization; | 2011 |
Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry.
Topics: Cholinergic Antagonists; Cost-Benefit Analysis; Drug Costs; Humans; Incontinence Pads; Mandelic Acid | 2012 |
[Oxybutynin-Kentera].
Topics: Humans; Mandelic Acids; Muscarinic Antagonists; Urinary Incontinence, Urge | 2007 |